[Erythrocyte elongation with 10% dextran 40,000: comparison of 2 substances].
A dosage-effect-study with two 10% dextrans 40,000 was carried out in 12 venous blood samples of healthy men aged from 21 to 45 years. Dextran A (trade name: Dextran 40,000 "Ebewe") and Dextran B (trade name: "Rheomacrodex") were added in dosages of 0.5 to 10 mg/ml whole blood and the elongation-index of erythrocytes at shearrate 50/sec was determined. From 1 mg up to 10 mg/ml the elongation-index in Dextran B showed a stronger decrease than in Dextran A. Under the highest dosage the difference was about 20%. So it was possible to show that in spite of identical molecular weight there are different effects on deformability of erythrocytes. This should be taken into account for parenteral treatment.
Krankenhaus der Barmherzigen Brüder, Graz-Eggenberg.
P
P
Költringer
W
W
Langsteger
P
P
Lind
G
G
Klima
F
F
Reisecker
O
O
Eber
D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects; D003911:Dextrans / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004907:Erythrocyte Deformability / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged
D003911:Dextrans
Erythrozytenelongation unter 10% Dextran 40,000: Vergleich zweier Substanzen.